Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$1.12 - $1.82 $6,244 - $10,146
-5,575 Reduced 27.29%
14,854 $19,000
Q1 2023

May 12, 2023

SELL
$1.25 - $2.0 $201,157 - $321,852
-160,926 Reduced 88.74%
20,429 $26,000
Q4 2022

Feb 10, 2023

SELL
$0.67 - $11.9 $604,527 - $10.7 Million
-902,280 Reduced 83.26%
181,355 $272,000
Q3 2022

Nov 14, 2022

BUY
$1.1 - $12.2 $1.19 Million - $13.2 Million
1,083,635 New
1,083,635 $1.28 Million
Q2 2022

Aug 12, 2022

SELL
$0.67 - $3.19 $92,911 - $442,370
-138,674 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.22 - $3.45 $23,760 - $36,925
-10,703 Reduced 7.17%
138,674 $414,000
Q4 2021

Feb 14, 2022

SELL
$2.36 - $3.57 $74,203 - $112,247
-31,442 Reduced 17.39%
149,377 $395,000
Q3 2021

Nov 15, 2021

BUY
$3.5 - $4.5 $586,995 - $754,708
167,713 Added 1279.67%
180,819 $656,000
Q2 2021

Aug 16, 2021

SELL
$3.09 - $4.54 $45,083 - $66,238
-14,590 Reduced 52.68%
13,106 $56,000
Q1 2021

May 17, 2021

SELL
$3.35 - $4.93 $96,446 - $141,934
-28,790 Reduced 50.97%
27,696 $94,000
Q4 2020

Feb 16, 2021

BUY
$2.35 - $3.74 $132,742 - $211,257
56,486 New
56,486 $197,000
Q1 2020

May 15, 2020

SELL
$1.27 - $3.0 $14,024 - $33,129
-11,043 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$1.6 - $2.43 $17,668 - $26,834
11,043 New
11,043 $23,000
Q1 2019

May 14, 2019

SELL
$2.0 - $2.65 $24,416 - $32,351
-12,208 Closed
0 $0
Q4 2018

Feb 15, 2019

BUY
$2.08 - $3.36 $25,392 - $41,018
12,208 New
12,208 $28,000

Others Institutions Holding RIGL

About RIGEL PHARMACEUTICALS INC


  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.96B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.